Close Menu

NEW YORK ─ Trinity Biotech on Tuesday announced its third quarter revenues increased 30 percent year over year to $32.0 million from $24.6 million.

For the quarter ended Sept. 30, Dublin-based Trinity Biotech's point-of-care revenues fell 46 percent to $2.1 million from $3.9 million in Q3 2019. The firm said its HIV product revenues continued to be impacted by logistical and testing constraints arising from the COVID-19 pandemic. Its point-of-care test revenues were unusually high in Q3 2019, the firm added.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.